Anders Vikström
About
Anders Vikström is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, Anders Vikström has authored 20 papers receiving a total of 620 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Anders Vikström's work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Anders Vikström is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Anders Vikström collaborates with scholars based in Sweden, Russia and France. Anders Vikström's co-authors include Fabrice Barlési, В. А. Горбунова, Achim Rittmeyer, Antonio Pazzola, Arnaud Scherpereel, Myung‐Ju Ahn, Joachim G.J.V. Aerts, Harry J.M. Groen, Elaine K. Wong and Joo-Hang Kim and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.
In The Last Decade
Anders Vikström
19 papers receiving 608 citations
Peers
Anders Vikström
J.W.G. van Putten Netherlands
Sonya C. Tate United Kingdom
Pranshu Bansal United States
Georgios Tsakonas Sweden
Antonin Schmitt France
D. Bisset United Kingdom
Virginia Burns United States
Kristell Marzin Germany
Tetsuo Ishizaki Japan
Naruo Yoshimura Japan
Citations per year, relative to Anders Vikström Anders Vikström (= 1×)
peers
J.W.G. van Putten
Countries citing papers authored by Anders Vikström
Since
Specialization
Citations
This map shows the geographic impact of Anders Vikström's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Vikström with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Vikström more than expected).
Fields of papers citing papers by Anders Vikström
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anders Vikström. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Vikström. The network helps show where Anders Vikström may publish in the future.
Co-authorship network of co-authors of Anders Vikström
This figure shows the co-authorship network connecting the top 25 collaborators of Anders Vikström. A scholar is included among the top collaborators of Anders Vikström based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anders Vikström. Anders Vikström is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wagenius, Gunnar, Anders Vikström, Anders Berglund, et al.. (2025). Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer – a population-based cohort study in Sweden. Acta Oncologica. 64. 415–422.
2.
Wagenius, Gunnar, Anders Vikström, Anders Berglund, et al.. (2024). First-line Treatment Patterns and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden: A Population-based Real-world Study with Focus on Immunotherapy. Acta Oncologica. 63. 198–205.
3.
Guan, Jikui, et al.. (2024). ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib. Frontiers in Oncology. 13. 1281510–1281510.
4.
Arriola, Edurne, Jana Jaal, Anne Edvardsen, et al.. (2023). Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer. The Oncologist. 29(4). e561–e569.
5.
Isaksson, Johan, Anders Berglund, Karly S. Louie, et al.. (2023). KRAS G12C Mutant Non–Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry. Clinical Lung Cancer. 24(6). 507–518.
6.
Nilsson, Fredrik, et al.. (2022). Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study. Acta Oncologica. 61(11). 1354–1361.
7.
Karlsson, Anna, Helena Cirenajwis, Hans Brunnström, et al.. (2019). A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. Scientific Reports. 9(1). 5207–5207.
8.
Vikingsson, Svante, Anders Vikström, Eva Brandén, et al.. (2019). Erlotinib treatment induces cytochrome P450 3A activity in non‐small cell lung cancer patients. British Journal of Clinical Pharmacology. 85(8). 1704–1709.
9.
Lal, Rohit, Gunnar Hillerdal, Riyaz Shah, et al.. (2015). Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 89(2). 154–160.
10.
Gréen, Henrik, et al.. (2014). A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 107. 186–195.
11.
Barlési, Fabrice, Arnaud Scherpereel, В. А. Горбунова, et al.. (2014). Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Annals of Oncology. 25(5). 1044–1052.
12.
Schmekel, Birgitta, Fredrik Winquist, & Anders Vikström. (2014). Analysis of breath samples for lung cancer survival. Analytica Chimica Acta. 840. 82–86.
13.
Rittmeyer, Achim, В. А. Горбунова, Anders Vikström, et al.. (2013). Health-Related Quality of Life in Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089). Journal of Thoracic Oncology. 8(11). 1409–1416.
14.
Lal, Rohit, Nawel Bourayou, Gunnar Hillerdal, et al.. (2013). Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. Health and Quality of Life Outcomes. 11(1). 163–163.
15.
Rittmeyer, Achim, Arnaud Scherpereel, В. А. Горбунова, et al.. (2013). Effect of maintenance bevacizumab (Bev) plus pemetrexed (Pem) after first-line cisplatin/Pem/Bev in advanced nonsquamous non-small cell lung cancer (nsNSCLC) on overall survival (OS) of patients (pts) on the AVAPERL (MO22089) phase III randomized trial.. Journal of Clinical Oncology. 31(15_suppl). 8014–8014.
16.
Barlési, Fabrice, Arnaud Scherpereel, Achim Rittmeyer, et al.. (2013). Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089). Journal of Clinical Oncology. 31(24). 3004–3011.
17.
Barlési, Fabrice, Arnaud Scherpereel, R. Gervais, et al.. (2011). AVAPERL1 (MO22089): Maintenance (mtc) bevacizumab (bev) with or without pemetrexed (pem) in patients (pts) with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) bev-cisplatin (cis)-pem: Interim safety data.. Journal of Clinical Oncology. 29(15_suppl). 7562–7562.
18.
Barlési, Fabrice, Javier de Castro, Antonio Pazzola, et al.. (2011). AVAPERL (MO22089): Final Efficacy Outcomes for Patients (pts) With Advanced Non-squamous Non-small Cell Lung Cancer (nsNSCLC) Randomised to Continuation Maintenance (mtc) with Bevacizumab (bev) or Bev + Pemetrexed (pern) After First-line (1L) Bev-cisplatin (cis)-pem Treatment (Tx). European Journal of Cancer. 47. 16–16.
19.
Hillerdal, Gunnar, Jens Benn Sørensen, Stein Sundstrøm, et al.. (2008). Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study. Journal of Thoracic Oncology. 3(11). 1325–1331.
20.
Hillerdal, Gunnar, Jens Benn Sørensen, Stein Sundstrøm, Anders Vikström, & Anders Hjerpe. (2008). Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study. The Clinical Respiratory Journal. 2(2). 80–85.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by J.W.G. van Putten Breakdown of academic impact, for papers by Sonya C. Tate Breakdown of academic impact, for papers by Pranshu Bansal Breakdown of academic impact, for papers by Georgios Tsakonas Breakdown of academic impact, for papers by Antonin Schmitt Breakdown of academic impact, for papers by D. Bisset Breakdown of academic impact, for papers by Virginia Burns Breakdown of academic impact, for papers by Kristell Marzin Breakdown of academic impact, for papers by Tetsuo Ishizaki Breakdown of academic impact, for papers by Naruo Yoshimura